Shilpa Medicare receives USFDA’s final approval for Zoledronic Acid Injection

16 May 2019 Evaluate

Shilpa Medicare has received US Food and Drug Administration’s (USFDA) final approval for its ANDA, Zoledronic Acid Injection, 4 mg/5 mL on May 15, 2019. Zoledronic Acid Injection, 4 mg/5 mL is a generic equivalent of reference listed drug (RLD) Zometa.

It is a bisphosphonate indicated for the treatment of Hypercalcemia of malignancy, Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy as recommended in the label approved by USFDA.

According to IQVIA MAT Q1 2019 data, the US market for Zoledronic Acid Injection, 4 mg/5 mL is approximately $10.8 Million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

520.65 -14.75 (-2.75%)
06-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1529.55
Dr. Reddys Lab 6315.00
Cipla 1423.40
Zydus Lifesciences 1021.00
Lupin 1679.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.